Rx Outsourcing Has Limits, Novartis' Vasella Says: R&D Supports Licensing
Executive Summary
A pharmaceutical company model based on in-licensing and marketing is not sustainable in the long run, Novartis CEO Daniel Vasella told the New York Society of Securities Analysts June 5.